



11 February 2019
Australian Securities Exchange Announcement

Total Brain partners with Mapmygenome to provide trial usage of its brain optimisation platform to all Mapmygenome users

- Total Brain expands its reach into the consumer market with this agreement
- Partnership will complement Mapmygenome's focus on preventative healthcare
- Mapmygenome users will have option to continue using the Total Brain service, post-trial, for a monthly fee

Total Brain (ASX: TTB) the world's first holistic brain optimisation platform, announced today that it is partnering with Mapmygenome, a molecular diagnostics company, to offer 3-month trials of its digital service to all Mapmygenome users.

Mapmygenome's product Genomepatri™ assesses inherited and acquired genomic health risks for 100+ conditions. The results provide valuable insight into genomic predisposition to several health conditions, traits, lifestyle tendencies, drug efficacy, and more, helping pre-empt disease.

The partnership will enable Mapmygenome users to complement their genetic health profile with brain health insights by assessing their 12 brain capacities and screening for risk of mental conditions.

Users will also have access to brain training to improve areas of weakness and optimise areas of strength.

At the end of the trial period, Mapmygenome users will have the option to continue using the Total Brain service for a monthly fee.

Powered by a scientifically validated digital brain assessment and by the largest standardised neuroscientific database in the world, Total Brain helps individuals assess, rank, screen and train their 12 brain capacities, covering the areas of emotion, feeling, cognition and self-control.

Mapmygenome offers personalized health solutions based on genetic tests that help people get to know more about themselves. By combining a genetic health profile and health history with genetic counseling, Mapmygenome provides actionable steps for individuals and their physicians toward a healthier life.

"We are excited to partner with Total Brain to offer our users deeper insight into their brains, and the opportunity to train their brains for healthier outcomes. Total Brain's offering is the

perfect complement to our Genomepatri™ report and is very much in line with our focus on preventative healthcare through healthy habits," Mapmygenome CEO, Anu Acharya said,

"Core brain capacities and mental conditions are not objectively measured or monitored, leading to a variety of issues for people at home and at work." CEO of Total Brain Louis Gagnon said.

"We are pleased to offer a free trial of our platform to Mapmygenome users, enabling them to proactively monitor their brain health and train healthy brain habits."

Total Brain is adding to its B2B channel partnerships by engaging B2C channel partners in targeted consumer markets and this agreement represents the second consumer channel partnership for Total Brain. The trial offer will be available to Mapmygenome users beginning in Q1 2019.

To learn more about Total Brain, visit www.totalbrain.com.

About Total Brain Limited (ASX: TTB)

Total Brain Limited (TTB) is a San Francisco and Sydney based company that has developed and sells Total Brain, the world's first brain optimisation platform powered by the largest standardized brain database and has over 600,000 registered users. Its SaaS platform helps people scientifically measure and optimize their brain capacities while managing the risk of impairment by common mental conditions. Benefits for employers and payers across the United States include productivity improvement and healthcare cost reduction. For more information, please visit www.totalbrain.com and follow us on [Twitter](#), [LinkedIn](#) and [Facebook](#).

Investor

Matt Morgan
Director
M: +61 408 019 458
E: info@totalbrain.com

Media

Nigel Kassulke
Canning Corporate Communications
M: +61 (0) 407 904 874
E: nkassulke@cannings.net.au